Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa.
Dao
Andrew
A
Department of Internal Medicine, California Pacific Medical Center, San Francisco, Calif, USA.
Tuan
Bertrand
B
Carlson
Nicole
N
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy; D044963:Biopsy, Fine-Needle / Q000009:adverse effects; D004322:Drainage; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects; D015942:Factor VIIa / Q000627:therapeutic use*; D006469:Hemoptysis / Q000188:drug therapy / Q000209:etiology; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D019934:International Normalized Ratio; D008168:Lung / Q000473:pathology; D008175:Lung Neoplasms / Q000601:surgery; D008297:Male; D009844:Oligosaccharides / Q000008:administration & dosage / Q000009:adverse effects*; D011655:Pulmonary Embolism / Q000517:prevention & control; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013896:Thoracic Diseases / Q000188:drug therapy* / Q000209:etiology
D000925:Anticoagulants; D015507:Drugs, Investigational; D009844:Oligosaccharides; D011994:Recombinant Proteins; C479958:idraparinux; D015942:Factor VIIa